Pushing the boundaries
of innovation in oncology.
Pushing the boundaries of
innovation in oncology.
At Cullinan Oncology, our pursuit to positively impact the lives of patients with cancer and their families is central to who we are and what we do. Our values reflect our intrinsic commitment to scientific innovation and our purposeful action with urgency. Our unique culture fuels our passion to create new standards of care for patients with cancer.
David P. Ryan
David P. Ryan serves on the Board of Directors and is the Clinical Director and the Chief of the Massachusetts General Hospital Cancer Center.
David holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. After completing his degree, David began his career at Columbia-Presbyterian Medical Center as an intern in Internal Medicine and became chief resident in the Internal Medicine department during his postdoctoral training. David joined Massachusetts General Hospital in 1998, where he has held positions of increasing responsibility over the past two decades, specializing in the research and treatment of patients with cancer.
Along with his professional experience, David has held many academic posts, including his current position of Shelby Memorial Professor of Medicine in the Field of Cancer Therapeutics at Harvard Medical School. The principal focus of David’s research is the design and implementation of clinical trials in gastrointestinal malignancies.
In addition to his professional, academic, and leadership roles, David devotes much of his time to numerous medical and hospital associations and committees. David is a member of the American Society for Clinical Oncology.
Jacquelyn Sumer
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Jackie is an industry expert with two decades of legal and strategic leadership experience, with proven skills in navigating a wide array of legal and compliance issues through clinical development and commercialization of cancer therapies. Prior to joining Cullinan, Jackie was Chief Legal and Compliance Officer at Genocea Biosciences, Inc., where she led all legal, intellectual property and compliance strategy and operations. Previously, Jackie was Vice President, Assistant General Counsel at Bristol Myers Squibb, where she led the Worldwide Hematology and Cell Therapy legal team, and prior to that, she was head of Celgene Corporation’s CAR T legal team, in both roles supporting the development and commercialization of multiple hematology medicines. Earlier in her career, Jackie held positions of increasing responsibility at Novartis Global Oncology and Novartis Pharmaceuticals Corporation, where she provided counsel on a range of matters relating to pre-clinical and clinical development, commercialization, employment, litigation and government investigations, and compliance.
Jackie began her legal career at Kaye Scholer, LLP, and clerked for the Honorable Gladys Kessler of the United States District Court in Washington, D.C. She holds a J.D. and a Master of Laws in international and comparative law from Duke University School of Law and a B.A. from Bucknell University.
Patrick Baeuerle, Ph.D.
Chief Scientific Officer
Patrick Baeuerle is the Chief Scientific Officer at Cullinan and an Executive Partner at MPM Capital. An immune oncology pioneer, Patrick has co-founded MPM oncology start-ups Harpoon, TCR², iOmx, Maverick and Werewolf.
Prior to joining Cullinan and MPM, Patrick served as Vice President, Research, and General Manager of Amgen Research Munich GmbH, where he was responsible for the development of BiTE antibody Blincyto®, which was approved in 2014 in less than three months by the U.S. FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. From 1998 to 2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier headed small molecule drug discovery at Tularik Inc., a publicly traded biotechnology company also acquired by Amgen (AMGN). From 1996-1998, he served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Patrick has published more than 238 PubMed-listed papers that have been cited more than 60,000 times to date. He has a Hirsh index of 120 and was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990 to 1997). He holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
Patrick currently serves on the Board of Directors of Harpoon, TCR² and Werewolf and on the Advisory Boards of Amphivena, ElevateBio, iOmx and Maverick. He also serves on the Investment Committee of MPM’s oncology-only crossover investment strategy.
Corinne Savill, Ph.D.
Chief Business Officer
Corinne Savill is the Chief Business Officer at Cullinan.
Prior to joining Cullinan, Corinne served as Global Head, Business Development and Licensing for Novartis Pharma. In this role, Corinne oversaw the execution and management of over 20 major transactions across multiple therapeutic areas including in-licensing, option and equity deals, spin-outs and divestments. Corinne started her career as a researcher at AstraZeneca and Imutran, a UK based Biotech, where she was Research Director. Novartis acquired Imutran in 1996 and Corinne was promoted to CEO. Since 2001, Corinne continued to hold increasingly senior leadership positions within Novartis. She was the European Head of the Transplant and Immunology Business, the Global Head Search and Evaluation for Business Development and prior to her last role the Global Head of Pricing and Market Access where she was responsible for the price and access strategies for the entire Novartis portfolio.
Corinne received a B.S. in Biochemistry from the University of Manchester (UK) and conducted her postgraduate research at University College and Middlesex School of Medicine (Ph.D.) and the Charing Cross Sunley Research Centre in London.
Jennifer Michaelson, Ph.D.
Chief Development Officer, Biologics
Jennifer is Chief Development Officer, Biologics at Cullinan.
Prior to joining Cullinan, Jennifer served as Senior Director and Executive Program Leader at Jounce Therapeutics, where she led the flagship ICOS antibody program, JTX-2011, from inception into Phase 2 development. An employee since company launch, Jennifer built and led multiple departments at Jounce, including Tumor Immunology, Pharmacology, and Preclinical Development. Jennifer was also a member of the Leadership Team at Jounce.
Previously, during her 10 year tenure at Biogen, Jennifer served as project leader for several monoclonal antibody and bispecific antibody programs in both the Oncology and Immunology therapeutic areas. Jennifer has also worked as a consultant at Third Rock Ventures for multiple stealth companies.
Jennifer received her B.A. in Biology from Princeton University and Ph.D from the Department of Cell Biology at Albert Einstein College of Medicine, and completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School.
Jeff Trigilio
Chief Financial Officer
Jeff Trigilio is Chief Financial Officer (CFO) at Cullinan.
Jeff is as an accomplished financial professional with biotechnology experience from operational as well as investment banking and capital markets roles. Prior to joining Cullinan Oncology, Jeff most recently served as CFO at Amylyx Pharmaceuticals where he established the company’s Finance and Accounting operations and oversaw the successful completion of a Series B financing. Jeff joined Amylyx after serving as a Vice President at BlueRock Therapeutics, an engineered cell and gene therapy company, where he played a leading role in building out the finance function and supporting its sale to Bayer AG in a transaction that valued BlueRock up to $1 billion. Previously, Jeff held corporate finance and strategy roles at Alexion Pharmaceuticals, a global biotechnology company focused on rare diseases, and in Healthcare Investment Banking and Equity Capital Markets at RBC Capital Markets and Credit Suisse.
Nadim Ahmed
President and Chief Executive Officer
Nadim Ahmed is the President and Chief Executive Officer of Cullinan Oncology.
Nadim has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb (BMS), where he served as President, Hematology and at Celgene Corporation (Celgene) where he served as President, Global Hematology & Oncology through its acquisition by BMS. As President, Hematology at BMS, Nadim oversaw multiple product launches and participated as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. During this time at Celgene, he successfully launched multiple cancer medicines, including Pomalyst®, Abraxane® and several key indications for Revlimid®. Nadim has worked with various treatment modalities, including small molecules, biologics and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.
Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping homeless families.
Jeffrey Jones, M.D., MPH, MBA
Chief Medical Officer
Dr. Jeffrey Jones is the Chief Medical Officer at Cullinan Oncology.
Dr. Jones has over 15 years of clinical development experience in academia and industry with skills ranging from clinical trials, drug development, medical education and healthcare management. Dr. Jones joins Cullinan from Bristol Myers Squibb (BMS) where, as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases, Dr. Jones led the development and lifecycle management strategy for Reblozyl®. Dr. Jones joined Celgene Corporation in 2017 as Clinical Strategy Lead for Lymphoma and Chronic Lymphocytic Leukemia, Global Clinical Research and Development. In that role he shaped clinical and business development strategy across a diverse portfolio of small and large molecules in early- through late-stage development.
Before joining the industry in 2017, Dr. Jones was Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University. While at Ohio State, Dr. Jones led the Chronic Lymphocytic Leukemia clinical research program and represented the Division of Hematology as Clinical Research Leader in the OSU Comprehensive Cancer Center. Dr. Jones holds an M.B.A. from The Ohio State University Fisher College of Business, a M.P.H. from the University of Texas School of Public Health and a M.D. from the University of Michigan Medical School, completing his residency in internal medicine at McGill University.
Rose Weldon
Vice President, Communications
Rose Weldon is the Vice President of Communications at Cullinan Oncology.
Rose is an expert communications professional in the pharmaceutical and biotech industries. Prior to joining Cullinan, she held roles of increasing responsibility at Bristol Myers Squibb, with leadership positions in Science and Commercial Communications, Global Hematology Communications, and Corporate Communications. Rose joined Bristol Myers Squibb after leading communications for the U.S. site for Otsuka. Previously, Rose held business communications roles at Sanofi. Rose earned her Master’s degree in Finance from La Salle University in Philadelphia.
Steve Andre
Chief Human Resources Officer
Steve Andre is Chief Human Resources Officer at Cullinan Oncology
Steve is an accomplished human resources executive with extensive experience in the life science industry. Prior to joining Cullinan Oncology, Steve provided consulting services for public and private biotech companies on strategic HR issues, growth strategy, compensation, and organizational development. Earlier, Steve served as the Chief Human Resources Officer at Tesaro where he led workforce strategy, organizational and performance development, and oversight of all aspects of Human Resources. Steve joined Tesaro after serving as Senior Vice President of Human Resources at Synageva, where he was responsible for global HR strategy and development through Synageva’s growth and eventual acquisition. Prior to Synageva, Steve held similar roles at multiple public biotech companies including AMAG Pharmaceuticals and Panacos.
Kevin A. Johnston
Chief Technical Operations Officer
Kevin A. Johnston is the Chief Technical Operations Officer at Cullinan.
With over 25 years of biopharmaceutical industry experience from early clinical development candidates through market applications, commercial product launches, and lifecycle management, Kevin is an industry expert in pharmaceutical development and manufacturing. Before joining the Cullinan Oncology, Kevin served as Vice President and Chief Technical Officer at Reata Pharmaceuticals, Inc. where he led the end-to-end pharmaceutical development, manufacturing operations, and supply chain strategy and execution. Prior to that role, he served as Vice President, Supply Chain & Logistics at TESARO, Inc. and has held positions of increasing responsibility in Pharmaceutical Development and Manufacturing in several companies including PRAECIS Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., and Precision Dermatology, Inc. Kevin holds an M.S. in Chemistry from Northeastern University, Boston and a B.S. in Chemistry from Lafayette College, Easton, PA.
Tony Rosenberg
Chairman of the Board
Tony Rosenberg is Chairman of the Board at Cullinan Oncology.
Previously, Tony was Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role, he oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics.
Tony brings more than 30 years of biotech operations and strategic management experience to Cullinan Oncology. He joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development, and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma) and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group.
Tony has a B.S. in Biological Sciences from the University of Leicester and a M.S. in Physiology from the University of London.
Tony currently serves as Chairman of the Board of Oculis SA and is on the Board of Directors of argenx BV and SiO2 Materials Science. Tony also serves as an advisor to PJT Ltd, UK.
Anne-Marie Martin, Ph.D.
Anne-Marie Martin is on the Board of Directors of Cullinan Oncology and currently Senior Vice President, Global Head of the Experimental Medicine Unit at GlaxoSmithKline. She is also a member of the Blood Profiling Atlas Consortium (Blood PAC), the Personalized Medicine Coalition and an executive committee member of the Partnership for Accelerating Cancer Therapies (FNIH-PACT).
Anne-Marie comes with a background of more than 20 years of medical experience in experimental medicine and research; and is an internationally trained scientist, thought leader and senior pharmaceutical executive. She has a successful track record in drug development, companion diagnostic development, and translational medicine across numerous therapeutic areas. Her experience in global regulatory science, medical affairs, business development, alliance management and global commercial insights convey her passion for people development, organizational culture, inclusion, and diversity.
Previously, Anne-Marie was Senior Vice President, Global Head of Precision Medicine at Novartis and Vice President, Head of Biomarker Research and Diagnostics at Adaptimmune. In addition to these roles, Anne-Marie’s career also includes a number of university appointments inclusive of teaching and research positions.
She received her undergraduate degree in biomedical sciences from Sheffield Hallam University, Sheffield, UK and a Ph.D. in Immunogenetics from MCP-Hahnemann University in Philadelphia.
Jon Wigginton, M.D.
Senior Advisor & Chairman of SAB
Jon Wigginton, M.D. is a Senior Advisor to Cullinan & Chairman of SAB.
Dr. Wigginton most recently served as the Chief Medical Officer at MacroGenics (NASDAQ:MGNX), where he led the company’s evolution of a fully-integrated, clinical-stage cancer immunotherapy organization. This included the translation of ten new molecules into the clinic, including early phase and/or proof-of-concept studies with bispecific molecules, checkpoint inhibitors, Fc-optimized antibodies and antibody drug conjugates, as well as the design and execution of registration-directed studies.
Previously, he served as the Therapeutic Area Head, Immuno-Oncology, Early Clinical Research at Bristol-Myers Squibb (NYSE: BMY). There, he oversaw early clinical development of the BMS Immuno-Oncology portfolio and co-led the BMS International Immuno-Oncology Network (II-ON). These efforts included several studies defining proof-of concept for both anti-PD-1 and anti-PD-L1 antibodies in patients with melanoma, lung cancer and renal cancer, and for the anti-PD-1/anti-CTLA-4 combination in patients with melanoma, work published subsequently in the New England Journal of Medicine. Additional trials from his group established proof-of-concept for anti-PD-1 in patients with hepatocellular carcinoma and Hodgkin’s disease.
During his academic career, Dr. Wigginton served as Head of the Investigational Biologics Section, Center for Cancer Research, NCI, where he led an integrated basic, translational and clinical research effort focused on combination immunotherapy in preclinical models and early clinical studies. He also served previously as president of the Society for Immunotherapy of Cancer (SITC). Dr. Wigginton received his M.D. and B.S. in Biology, with distinction, from the University of Michigan.
Stephen Webster
Stephen Webster has served on our board of directors since September 2020. Stephen served as the Chief Financial Officer of Spark Therapeutics, Inc. from July 2014 until its acquisition by Roche Holding AG for $4.8 billion in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals Inc. from July 2012 until its acquisition by Cubist Pharmaceuticals Inc. in October 2013. Stephen currently serves on the board of directors of NextCure, Inc. (Nasdaq: NXTC), Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc) (Nasdaq: NBRV) and TCR2 (Nasdaq: TCRR). Stephen received an A.B. in Economics from Dartmouth College and an M.B.A. in Finance from The Wharton School of the University of Pennsylvania. We believe Stephen is qualified to serves as a member of our board of directors due to his extensive experience in the biopharmaceutical industry, including his prior experience as a chief financial officer and in other management positions.
Raymond T. Keane, Esq.
Chief Legal Officer
Raymond T. Keane, Esq. is the Chief Legal Officer at Cullinan.
Ray has served as our Chief Legal Officer since December 2020. Before joining the Company, Ray served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Intarcia Therapeutics, Inc. from September 2013 through April 2020. Prior to this, he served at Ariad Pharmaceuticals Inc., or Ariad, from 2008 through 2013 as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer. Prior to his tenure at Ariad, Ray served in increasing roles of responsibility at Bristol-Myers Squibb from 1988 until 2008, most recently as Chief Counsel, Global Marketing and Strategic Development. Ray has also served on various private company boards of directors. Ray holds a B.A. from Fordham University and a J.D. from Fordham University School of Law.
Thomas Ebeling
Thomas Ebeling is on the Board of Directors of Cullinan and a member of the Advisory Board of the UBS Oncology Impact Fund by MPM Capital.
After earning a degree in psychology in Hamburg, Thomas began his career with Reemtsma in 1987, where he served as the product manager responsible for the “West” brand, among other duties. In 1991, he moved to Pepsi-Cola Germany, where he served as a marketing manager. In 1993, he was appointed Marketing Director for the entire beverage portfolio. Starting in 1994, he was National Sales and Franchise Director for the retail and restaurant sales of Pepsi-Cola. In 1996, he was appointed General Manager of Pepsi-Cola Germany.
In 1997, Thomas moved to Novartis, where he served as General Manager of Novartis Nutrition for Germany and Austria. In 1998, he assumed worldwide leadership of the Novartis Nutrition Division. In this position, he headed the three business units Medical Nutrition, Health Nutrition and Consumer Retail Brands, where, among other duties, he was responsible for the leading U.S. baby food brand Gerber. In 1998, he was appointed to the Novartis Executive Committee. From 2000 to October 2007, he served as CEO of the global Novartis pharmaceuticals business. Under his leadership, the company’s revenues more than doubled from US $11 billion to US $22.6 billion, after which he was CEO of the Novartis Consumer Health Division from 2007 to 2009.
From 2009 to 2018, Thomas served as CEO of ProSiebenSat.1 Media SE, and has been a member of the supervisory board of Bayer AG since 2012 as well as a member of board of directors at Sivantos (Hearing Aids) since 2016 and GFK since 2017.
Briggs Morrison, M.D.
Clinical Advisor
Briggs W. Morrison is a Clinical Advisor to Cullinan and Executive Partner at MPM Capital. Briggs is CEO and a member of the Board of Directors of Syndax Pharmaceuticals, Inc., an MPM portfolio company.
Prior to joining Syndax, Briggs served as Chief Medical Officer and Executive VP for “Global Medicines Development” at AstraZeneca (ADR). His career also includes distinguished roles at AstraZeneca, Pfizer (PFE) and Merck (MRK). At AstraZeneca, he was head of global medicines development, where he oversaw all clinical development functions and late- stage clinical development projects. As Head of Clinical Development at Pfizer, he oversaw Phase I-III development and operations for all therapeutic areas before being appointed the head of Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses. While serving as head of Oncology Development at Merck, Briggs oversaw the development and approval of vorinostat (Zolinza®) for the treatment of cutaneous T-cell lymphoma. Briggs formerly served as Chairman of the Board of Transcelerate, an industry-funded company charged with improving aspects of clinical trials.
Briggs received his B.S. (Biology) from Georgetown University and his M.D. from the University of Connecticut, and completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School and additional post-doctoral work at the Dana-Farber Cancer Institute. Briggs trained in Internal Medicine at the Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute.
Briggs serves on the Board of Directors of Oncorus and Repare Therapeutics, and is a member of the investment committee of the UBS Oncology Impact Fund by MPM Capital.
